After an oral administration of 100 mug/kg dose, the investigated prostaglandins: - PGF2alpha, PGE2 and a synthetic PGE2 derivative: FCE-20700, - exerted a significant effect on cAMP and cGMP content of both parts (antral and fundic) of gastric mucosa, resulting in an elevated cAMP/cGMP ratio, while 6-keto-PGF1alpha, the stable break-down product of prostacyclin, was inactive. Since the above-mentioned phenomenon seems to be proportionate to the cytoprotective (anti-ulcerogenic) property of the investigated prostaglandins, this cAMP/cGMP ratio ''shift'' is interpreted as a probable (molecular) sign of the reparative, (anti-ulcerogenic) processes.
